Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADRB1 | P08588 | 1/20 | 0.55 |
| ▸ | ALOX5 | P09917 | 1/20 | 0.51 |
| ▸ | MGLL | Q99685 | 1/20 | 0.50 |
| ▸ | MAPT | P10636 | 2/20 | 0.49 |
| ▸ | DRD2 | P14416 | 2/20 | 0.48 |
| ▸ | DRD3 | P35462 | 2/20 | 0.48 |
| ▸ | NPC1 | O15118 | 1/20 | 0.48 |
| ▸ | FADS1 | O60427 | 1/20 | 0.47 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.47 |
| ▸ | P2RX7 | Q99572 | 1/20 | 0.44 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.44 |
| ▸ | ALKBH5 | Q6P6C2 | 1/20 | 0.43 |
| ▸ | DCTPP1 | Q9H773 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5788222 | 0.93 | ADRB1 (0.49) | ADRB1ALOX5MGLLMAPTDRD2 | |
| SCHEMBL2884739 | 0.81 | HTR3E (0.51) | ADRB1MGLLMAPTNPC1 | |
| SCHEMBL2300655 | 0.81 | CYP1A1 (0.50) | ADRB1MAPT | |
| SCHEMBL1663489 | 0.80 | ADRB1 (0.59) | ADRB1ALOX5MGLLMAPTDRD2 | |
| SCHEMBL20956923 | 0.80 | DRD2 (0.49) | DRD2DRD3KCNH2 | |
| SCHEMBL150081 | 0.80 | ALOX5 (0.60) | ADRB1ALOX5MGLLMAPTDRD2 | |
| Hydrochloric Acid SCHEMBL1584087 | 0.79 | ADRB1 (0.57) | ADRB1ALOX5MGLLMAPTDRD2 | |
| SCHEMBL2300656 | 0.79 | TGFBR1 (0.40) | ALOX5MAPTDRD2 | |
| SCHEMBL2301613 | 0.79 | TGFBR1 (0.42) | ALOX5MAPTDRD2 | |
| SCHEMBL25079569 | 0.78 | DDB1 (0.66) | ADRB1ALOX5MGLLMAPTDRD2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 27 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12441714-B2 | Pyrrolidine compounds | ELI LILLY AND COMPANY (US) | 2025-10-14 | — | — | US | disclosed |
| US-20220169636-A1 | PYRROLIDINE COMPOUNDS | ELI LILLY AND COMPANY | 2022-06-02 | — | — | US | disclosed |
| US-20220169636-A1 | PYRROLIDINE COMPOUNDS | ELI LILLY AND COMPANY | 2022-06-02 | — | — | US | disclosed |
| EP-3980409-A1 | PYRROLIDINE COMPOUNDS | ELI LILLY AND COMPANY (US) | 2022-04-13 | — | — | EP | disclosed |
| US-11286249-B2 | Pyrrolidine compounds | ELI LILLY AND COMPANY (US) | 2022-03-29 | — | — | US | disclosed |
| CN-114008021-A | Pyrrolidine compounds | 伊莱利利公司 | 2022-02-01 | — | — | CN | disclosed |
| US-20210253559-A1 | PYRROLIDINE COMPOUNDS | ELI LILLY AND COMPANY | 2021-08-19 | — | — | US | disclosed |
| US-20210253559-A1 | PYRROLIDINE COMPOUNDS | ELI LILLY AND COMPANY | 2021-08-19 | — | — | US | disclosed |
| WO-2020247429-A1 | PYRROLIDINE COMPOUNDS | ELI LILLY AND COMPANY (US) | 2020-12-10 | — | — | WO | disclosed |
| WO-2020247429-A1 | PYRROLIDINE COMPOUNDS | ELI LILLY AND COMPANY (US) | 2020-12-10 | — | — | WO | disclosed |
| US-20060264673-A1 | Copper-catalyzed formation of carbon-heteroatom and carbon-carbon bonds | MASSACHUSETTS INSTITUTE OF TECHNOLOGY (US) | 2006-11-23 | — | — | US | disclosed |
| US-7115784-B2 | Copper-catalyzed formation of carbon-heteroatom and carbon-carbon bonds | MASSACHUSETTS INSTITUTE OF TECHNOLOGY (US) | 2006-10-03 | — | — | US | disclosed |
| US-20050215794-A1 | Copper-catalyzed formation of carbon heteroatom and carbon-carbon bonds | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2005-09-29 | — | — | US | disclosed |
| US-6867298-B2 | Copper-catalyzed formation of carbon-heteroatom and carbon-carbon bonds | MASSACHUSETTS INSTITUTE OF TECHNOLOGY | 2005-03-15 | — | — | US | disclosed |
| CN-1518534-A | Copper-catalyzed carbon-heteroatom and carbon-carbon bond formation | 麻省理工学院 | 2004-08-04 | — | — | CN | disclosed |
| US-6759554-B2 | Copper-catalyzed formation of carbon-heteroatom and carbon-carbon bonds | MASSACHUSETTS INSTITUTE OF TECHNOLOGY | 2004-07-06 | — | — | US | disclosed |
| EP-1390340-A1 | COPPER-CATALYZED FORMATION OF CARBON-HETEROATOM AND CARBON-CARBON BONDS | MASSACHUSETTS INSTITUTE OF TECHNOLOGY (US) | 2004-02-25 | — | — | EP | disclosed |
| US-20040019216-A1 | Copper-catalyzed formation of carbon-heteroatom and carbon-carbon bonds | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2004-01-29 | — | — | US | disclosed |
| US-20030065187-A1 | Copper-catalyzed formation of carbon-heteroatom and carbon-carbon bonds | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2003-04-03 | — | — | US | disclosed |
| WO-2002085838-A1 | COPPER-CATALYZED FORMATION OF CARBON-HETEROATOM AND CARBON-CARBON BONDS | MASSACHUSETTS INSTITUTE OF TECHNOLOGY (US) | 2002-10-31 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060264673-A1 | Copper-catalyzed formation of carbon-heteroatom and carbon-carbon bonds | ADH5, CBR3, ALDH3A1 | ADRB1 4040/4885ALOX5 453/4885MGLL 3207/4885 |
| US-20050215794-A1 | Copper-catalyzed formation of carbon heteroatom and carbon-carbon bonds | CBR3, ADH5, IDH1 | ADRB1 3978/4885ALOX5 335/4885MGLL 3577/4885 |
| US-12441714-B2 | Pyrrolidine compounds | ADCYAP1R1, AVPR2, NPPA | ADRB1 1568/4885ALOX5 1806/4885MGLL 3436/4885 |
| US-20030065187-A1 | Copper-catalyzed formation of carbon-heteroatom and carbon-carbon bonds | ADH5, CBR3, ALDH3A1 | ADRB1 4040/4885ALOX5 453/4885MGLL 3207/4885 |
| US-20040019216-A1 | Copper-catalyzed formation of carbon-heteroatom and carbon-carbon bonds | ADH5, CBR3, ALDH3A1 | ADRB1 4040/4885ALOX5 453/4885MGLL 3207/4885 |
| US-11286249-B2 | Pyrrolidine compounds | PAH, OTC, PPOX | ADRB1 2131/4885ALOX5 877/4885MGLL 4599/4885 |
| US-20210253559-A1 | PYRROLIDINE COMPOUNDS | PAH, OTC, PPOX | ADRB1 2131/4885ALOX5 877/4885MGLL 4599/4885 |
| US-20220169636-A1 | PYRROLIDINE COMPOUNDS | ADCYAP1R1, AVPR2, NPPA | ADRB1 1568/4885ALOX5 1806/4885MGLL 3436/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.